Denmark

Denmark's primary regulatory authority for health products is the Danish Medicines Agency (DKMA), operating under the Ministry of the Interior and Health. Pharmaceuticals are governed by the Medicines Act (Lagemiddelloven, Consolidated Act No. 99 of 16 January 2018 and subsequent amendments), while medical devices and in vitro diagnostics fall under EU Regulations MDR 2017/745 and IVDR 2017/746, respectively, as transposed into Danish law. Denmark is a full EU Member State and participates in the European Medicines Agency (EMA) centralised procedure for eligible products, as well as the mutual recognition procedure (MRP) and decentralised procedure (DCP) for nationally authorised medicines. Digital health solutions are increasingly reviewed under a combination of the Medical Device Regulations, the EU AI Act, and national digital health governance frameworks coordinated by the Danish Health Data Authority (Sundhedsdatastyrelsen). The DKMA also collaborates closely with the Danish Health Authority (Sundhedsstyrelsen) on clinical guidelines and health technology assessment processes.

For pharmaceutical submissions, Denmark accepts dossiers prepared in the International Council for Harmonisation Common Technical Document (ICT-CTD) format, consistent with EMA standards. Applicants based outside the European Economic Area must appoint a locally established EU-based Marketing Authorisation Holder or legal representative. Medical device manufacturers must engage an EU-recognised Notified Body for conformity assessment and affix CE marking prior to market entry; Danish Notified Bodies are accredited through the Danish Accreditation Fund (DANAK). Recent notable reforms include accelerated adaptation to the EU MDR and IVDR transitional timelines, stricter post-market surveillance requirements, and the integration of digital therapeutics guidance aligned with evolving EU frameworks. Denmark has also strengthened pharmacovigilance obligations and increased transparency in pricing and reimbursement dossiers as part of broader EU regulatory harmonisation efforts.

Public procurement of health products in Denmark is primarily organised through the central government and the five administrative regions (Capital Region, Region Zealand, Region of Southern Denmark, Central Denmark Region, and North Denmark Region), which are responsible for delivering hospital-based healthcare. The Ministry of the Interior and Health sets overarching health policy, while the Danish Regions (Danske Regioner) coordinates joint procurement strategies across the regional hospital systems. A key centralised procurement vehicle is Amgros I/S, a non-profit company owned by the five regions that manages tendering and purchasing of pharmaceuticals for hospital use. Amgros conducts annual tender rounds, negotiates framework agreements, and manages the formulary for hospital medicines, resulting in significant volume-based price leverage. Medical devices and diagnostics are procured through regional and hospital-level tenders, often coordinated via SKI (Staten og Kommunernes Indkobsfallesskab), a national public procurement cooperative serving both state and municipal entities. All public tenders are subject to EU public procurement directives (Directive 2014/24/EU), implemented through the Danish Public Procurement Act (Udbudsloven).

The private healthcare sector in Denmark is relatively limited compared to the public system, but it includes private hospitals, clinics, and insurance-funded services that procure health products through standard commercial channels and direct supplier agreements. Denmark does not rely on international donor-funded procurement mechanisms such as UNICEF Supply Division, the Global Fund, USAID, or Gavi, as it is a high-income country and a donor nation itself. However, Denmark actively participates in joint procurement initiatives at the EU level, including the EU Joint Procurement Agreement for medical countermeasures. Reimbursement for outpatient pharmaceuticals is managed through the DKMA's reimbursement system, with the Reimbursement Committee (Reimbursement Board) assessing therapeutic value and cost-effectiveness. Denmark does not have explicit local manufacturing preference policies, but sustainability and supply chain resilience considerations have gained prominence in procurement criteria following disruptions experienced during the COVID-19 pandemic.